Clorox – The patron products giant saw an enormous earnings beat. It is also rebounding from last 12 months’s cyberattack. “Things are back online, and there is tremendous demand for his or her product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for two.2 million cars over a warning light issue. Remember, our Super Six means do away with Tesla; no more Magnificent Seven. Jim said possibly do not buy the slide. “I urge people to rethink that perhaps [Elon Musk] isn’t as interested as being CEO anymore.” Bristol-Myers Squibb – The drugmaker’s shares were up after an earnings beat and a higher-than-expected 2024 outlook. “A five-year plan on Bristol Myers,” Jim said, unless the company can get more drugs to work out. Members of the CNBC Investing Club know that Eli Lilly is our favourite drug stock. Abbvie – The drugmaker delivered a mixed quarter but raised its forecast. Abbvie lost exclusivity on blockbuster Humira. The stock holding up shows “they’ll have the opportunity to handle the valley,” Jim said. Exxon and Chevron – The 2 oil majors were up on earnings. Chevron was 3% higher after raising its dividend after rumors that it could be unable to pay it. Jim said, “If you’ve to own oil, we like Coterra ” and own it for the Club. He likes Chevron higher than Exxon.(*6*)(*6*)(*6*)(*6*)